Pasar al contenido principal

VALIDACION DE LA INHIBICION DUAL G9A/GSK-3B COMO NUEVA ESTRATEGIA TERAPEUTICA PARA EL DETERIORO COGNITIVO Y LA ENFERMEDAD DE ALZHEIMER.

PID2022-139016OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beta-hydroxybutyrate counteracts the deleterious effects of a saturated high-fat diet on synaptic AMPAR receptors and cognitive performance

  • Rojas, Rocío|||0000-0002-0509-1023
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Castellanos, Aida
  • Griego, Ernesto
  • Martínez, Marc
  • de Dios Navarro-López, Juan
  • Jiménez-Díaz, Lydia|||0000-0001-9121-0334
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
  • Soto del Cerro, David
  • Castillo, Pablo E.
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Casals, Nuria|||0000-0002-6719-4300
  • Fadó, Rut|||0000-0002-3293-2342
The ketogenic diet -high in fat and low in carbohydrates- and intermittent fasting have gained popularity not only for weight management but also for their potential to delay cognitive decline associated with neurodegenerative diseases and aging. However, adherence to these diets remains low due to their restrictive nature and undesirable side effects. Both dietary approaches stimulate hepatic production of ketone bodies, primarily β-hydroxybutyrate (BHB), which serves as an alternative energy source for neurons. Here, we investigated whether BHB supplementation could mitigate AMPA receptor trafficking impairments, synaptic dysfunction, and cognitive decline induced by metabolic challenges such as a saturated fat-rich diet. Our results show that, in cultured primary cortical neurons, exposure to palmitic acid decreases surface levels of glutamate GluA1-containing AMPA receptors, whereas unsaturated fatty acids and BHB increase these levels. Furthermore, physiological concentrations of BHB (1-2 mM) countered the adverse effects of palmitic acid on synaptic GluA1 and GluA2 levels in hippocampal neurons, restoring AMPA receptor-mediated synaptic transmission. In hippocampal slices, BHB also reversed palmitate-induced impairments in excitability and synaptic plasticity (long-term potentiation; LTP). Additionally, daily intragastric administration of BHB (100 mg/kg/day for two months) prevented deficits in recognition and spatial memory induced by a saturated fat-rich diet (49% of calories from fat) in mice. In summary, our findings underscore the significant impact of fatty acids and ketone bodies on AMPA receptor abundance, synaptic function, and neuroplasticity, shedding light on the potential use of BHB as a dietary supplement to counteract cognitive impairments linked to metabolic diseases.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of Gadd45a Expression in Mice Leads to Cognitive and Synaptic Impairment Associated with Alzheimer’s Disease Hallmarks

  • Griñán-Ferré, Christian
  • Jarne-Ferrer, Júlia
  • Bellver-Sanchis, Aina
  • Ribalta-Vilella, Marta
  • Barroso, Emma
  • Salvador Sánchez, Jesús María
  • Jurado-Aguilar, Javier
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
  • Pallàs, Mercè
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Gadd45 genes have been implicated in survival mechanisms, including apoptosis, autophagy, cell cycle arrest, and DNA repair, which are processes related to aging and life span. Here, we analyzed if the deletion of Gadd45a activates pathways involved in neurodegenerative disorders such as Alzheimer’s Disease (AD). This study used wild-type (WT) and Gadd45a knockout (Gadd45a−/−) mice to evaluate AD progression. Behavioral tests showed that Gadd45a−/− mice presented lower working and spatial memory, pointing out an apparent cognitive impairment compared with WT animals, accompanied by an increase in Tau hyperphosphorylation and the levels of kinases involved in its phosphorylation in the hippocampus. Moreover, Gadd45a−/− animals significantly increased the brain’s pro-inflammatory cytokines and modified autophagy markers. Notably, neurotrophins and the dendritic spine length of the neurons were reduced in Gadd45a−/− mice, which could contribute to the cognitive alterations observed in these animals. Overall, these findings demonstrate that the lack of the Gadd45a gene activates several pathways that exacerbate AD pathology, suggesting that promoting this protein’s expression or function might be a promising therapeutic strategy to slow down AD progression., This research was funded by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) PID2021-122116OB-100 (M.V.-C.), PID2022-139016OA-100 (C.G.-F), and PDC2022-133441-100 (M.P.), Generalitat de Catalunya (2021 SGR 00357). This study was co-financed by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092). A.B-S acknowledges the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021 FISDU 00182). This study was also partly supported by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and CIBER de Enfermedades Neurodegenerativas (CIBERNED) are a Carlos III Health Institute project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, L.
  • Romero, Fernando
  • Dong, M.
  • Samadi, A.
  • Almendros, Pedro
  • Iriepa, I.
  • Bautista-Aguilera, O. M.
  • Rodríguez-Fernández, M. M.
  • Solana-Manrique, C.
  • Sanchis, I.
  • Mora-Morell, A.
  • Rodríguez, A. C.
  • Sánchez-Pérez, A. M.
  • Knez, D.
  • Gobec, S.
  • Bellver-Sanchis, A.
  • Pérez, B.
  • Dobrydnev, A. V.
  • Artetxe-Zurutuza, A.
  • Matheu, A.
  • Siwek, A.
  • Wolak, M.
  • Satała, G.
  • Bojarski, A. J.
  • Doroz-Płonka, Agata
  • Handzlik, J.
  • Godyń, J.
  • Więckowska, A.
  • Paricio, N.
  • Griñán-Ferré, C.
  • Hansen, F. K.
  • Marco-Contelles, José
Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC = 0.012 μM and 0.035 μM, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson’s disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer’s disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models., JMC thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and UCJC [Grant: “In vivo analysis of new analogues of Contilisant (MITOPI) (2022)”] for support. This work is part of the MINA-CM program (number S2022/BMD-7236), funded by the call for the implementation of programs of R&D activities between research groups of the Community of Madrid in Biomedicine 2022 (Order 1171/2022). MTP thanks MINA- CM program (number S2022/BMD-7236) for a contract. MMRF and AP thank Comunidad de Madrid for a “Investigo” Contract (2022-23). II thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. AS thanks the UAEU for financial support by Strategic Research Program-Zayed Center for Health Sciences (Grant # G00003680) and by the SURE PLUS (grant #: G00003976) (2022). CGF thanks AEI (MINECO-FEDER, Government of Spain; Grant PID2022-139016OA-I00), Generalitat de Catalunya (Grant 2021 SGR 00357), and AGAUR (Grant 2023Llavor005). ABS acknowledges the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021FISDU 00182). Some strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). DK and SG thank the Slovenian Research and Innovation Agency (Research Core Funding grant P1-0208, and project J1-3018) for finnancial support. LSH wants to greatfully acknowledge experimental support by Philipp Stegen.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-based Therapy of Parkinson’s Disease

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, Linda
  • Diez-Iriepa, Daniel
  • Iriepa, Isabel
  • Siwek, Agata
  • Wolak, Małgorzata
  • Satała, Grzegorz
  • Bojarski, Andrzej J.
  • Doroz-Płonka, Agata
  • Handzlik, Jadwiga
  • Godyń, Justyna
  • Dallemagne, Patrick
  • Rochais, Christophe
  • Davis, Audrey
  • Since, Marc
  • Pérez, Belén
  • Bellver-Sanchis, Aina
  • Irisarri, Alba
  • Pallàs, Mercè
  • Solana-Manrique, Cristina
  • López-Muñoz, Francisco
  • Ismaili, Lhassane
  • Griñán-Ferré, Christian
  • Paricio, Nuria
  • K. Hansen, Finn
  • Więckowska, Anna
  • Marco-Contelles, José
This article belongs to the Special Issue 25th Anniversary of IJMS: Updates and Advances in Molecular Pathology, Diagnostics, and Therapeutics, Herein, we have identified the polyfunctionalized 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid derivative MTP150 for the treatment of neurodegenerative diseases owing to its efficacy in reducing protein aggregation, modulating matrix metalloproteinase activity, mitigating neuroinflammation, and enhancing DNA damage repair pathways across in vivo Caenorhabditis elegans models of Alzheimer’s disease, Parkinson’s disease (PD), and Huntington’s disease. Further experiments in an in vivo Drosophila model of PD showed that MTP150 increased motor performance, reduced oxidative stress levels, and restored mitochondrial function in model flies. In addition, MTP150 exhibited neuroprotective effects in PD model cells, thereby supporting its therapeutic potential for this disease., J.M.-C. thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and Comunidad de Madrid (IND2023/BMD-27036) for support. I.I. thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. A.P.-P. is grateful to Comunidad de Madrid (IND2023/BMD27036) for a fellowship. This work was supported by grants PID2022-139016OA-I00 and PDC2022-133441-I00, funded by MICIU/AEI/10.13039/501100011033 and FEDER, UE, awarded to C.G.-F. and M.P.; Generalitat de Catalunya (2021 SGR 00357) to CGF and MP; and University of Valencia (UVINV-AE-3664989) to NP. This study was co-financed by Secretaria d’Universitats i Recerca de Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092; Llavor 005 and 007; to CGF). The work of L.S.-H. and F.K.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), GRK2873 (494832089)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of anti-inflammatory pathways by polyunsaturated fatty acid signaling may protect neurodevelopment in children prenatally exposed to methylmercury

  • Bartra, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferran
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Sanfeliu, Coral
Mercury is ubiquitous in the environment. Substantial levels of its organic form, methylmercury, pose a risk to fetal neurodevelopment through the maternal diet. Conversely, nutrients such as the polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (AA) promote neurodevelopment. We aimed to elucidate the neuroprotective role of PUFA signaling against prenatal methylmercury exposure in a Mediterranean fish-consuming area, addressing a critical gap in understanding nutritional modulation of neurotoxicity., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministerio de Ciencia: Innovación y Universidades and the Agencia Estatal de Investigación, MICIU/AEI/10.13039/501100011033 grants PID2019-106285RB, PID2020-118127RB and PID2022-139016OA-100, and grant PDC2021-121096 co-funded by the European Union - Next Generation EU/PRTR; the Spanish Instituto de Salud Carlos III (ISCIII) and co-funded by the Europen Union, grants FI21/00193 and CPII21/00003; the ISCIII grants FIS/FEDER 19/1338, 16/1288, 23/1578 and MS20/0006; the European Union grant H2020 874583; the Spanish Ministry of Universities (Margarita Salas Grant MS21-133) and co-funded by European Union - Next Generation EU; the Generalitat Valenciana, grants AICO/2020/285 and CIAICO/2021/132; and the Generalitat de Catalunya, AGAUR grant 2021-SGR-357., Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d] imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer's disease

  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Manik, Aleksandra
  • Diez Iriepa, Daniel|||0000-0002-8575-1246
  • Szałaj , Natalia
  • Marco Contelles, José Luis
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Martínez Alonso, Borja
  • Guarnizo Herrero, Víctor|||0000-0001-9323-3388
  • Torrado Durán, Guillermo|||0000-0002-8865-2083
As part of a project aimed at the pharmacological optimization of Contilisant, herein we describe molecular modelling studies that led to the identification of MBA-159 as a new polyfunctionalized, multitarget-directed ligand and a promising drug candidate for the treatment of Alzheimer?s disease. We synthesized MBA-159 and conducted comprehensive in vitro and in vivo evaluations. In in vivo studies MBA-159 demonstrated favourable pharmacokinetics, anti-amnesic properties and significantly improved non-spatial memory (contextual and recognition memory) in a mouse model of scopolamine-induced amnesia. Additionally, MBA-159 showed a tendency to increase synaptic plasticity biomarkers and reduce neuroinflammatory trends (assessed by qPCR), as well as cognitive enhancement in a senescence-accelerated prone mouse 8 model., Ministerio de Ciencia e Innovación, Ministerio de Economía, Comercio y Empresa
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

  • Toledano Pinedo, Mireia
  • Porro Pérez, Alicia
  • Paricio, Nuria
  • Griñan Ferré, Christian
  • Hanssen, Finn
  • Schaker-Hubner, Linda
  • Romero, Fernando
  • Dong, Ming
  • Samadi, Abdelouahid
  • Almendros, Pedro
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Rodríguez Fernández, M. Mercedes
  • Marco Contelles, José Luis
Herein, we describe the design, synthesis, and biological evaluation of 15 Contilisant+Tubastatin A hybrids. These ligands are polyfunctionalized indole derivatives developed by juxtaposing selected pharmacophoric moieties of Contilisant and Tubastatin A to act as multifunctional ligands. Compounds 3 and 4 were identified as potent HDAC6 inhibitors (IC50 = 0.012 mu M and 0.035 mu M, respectively), so they were further evaluated in Drosophila and human cell models of Parkinson's disease (PD). Both compounds attenuated PD-like phenotypes, such as motor defects, oxidative stress, and mitochondrial dysfunction in PD model flies. Ligands 3 and 4 were also studied in the transgenic Caenorhabditis elegans CL2006 model of Alzheimer's disease (AD). Both compounds were nontoxic, did not induce undesirable animal functional changes, inhibited age-related paralysis, and improved cognition in the thrashing assay. These results highlight 3 and 4 as novel multifunctional ligands that improve the features of PD and AD hallmarks in the respective animal models., Ministerio de Ciencia, Innovación y Universidades